LTG-001 demonstrated rapid absorption with a Tmax of approximately 1.5 hours. The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Dr. Edward Paul answers the question: 'How Does Chronic Pain Differ From Acute?' — -- Question: What Is Chronic Pain And How Does It Differ From Acute Pain? Answer: Chronic pain and acute pain ...

Pain has the potential to affect various aspects of a person’s life, from disrupting one’s daily routine to negatively impacting emotional well-being. It’s also one of the most common reasons that ...

For pediatric nonoperative fractures and sprains, adding acetaminophen or hydromorphone to ibuprofen does not provide better ...

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

USA: Researchers have found in a new study that in adults with acute and subacute low back pain, a biopsychosocial-oriented ...

The FDA approved prescription suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults, the agency announced Thursday.

With the world in an opioid crisis, the development of non-opioid analgesics has become more urgent. A series of Phase 3 clinical trials into a novel oral, non-opioid painkiller has found that it’s ...

Researchers evaluated the effect of a combined emergency department and outpatient clinic acupuncture intervention on acute musculoskeletal pain.

A neural circuit hidden in an understudied region of the brain plays a critical role in turning temporary pain into pain that ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...